2025年5月14日，施能康公司（SynerK），一家专注于开发RNAi疗法的领先生物制药公司，宣布其使用自主知识产权的新型核酸药物递送技术平台GalNexus研发的首款siRNA药物SNK-2726已获得国家药品监督管理局药品审评中心（CDE）和美国FDA的新药临床试验（IND）批准，并成功完成中国I期临床试验首例受试者入组及给药。

2025年2月27日，施能康公司（Synerk）宣布，公司自主研发的靶向血管紧张素原（AGT）的寡核苷酸（siRNA）候选药物SNK-2726已获得美国食品药品监督管理局（FDA）临床试验申请（IND）批准。

December 27, 2024 - Hangzhou Sino-US Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine"), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), and SynerK PharmaTech (Suzhou) Co., Ltd. (hereinafter referred to as "SynerK") have reached a strategic cooperation. The two parties will jointly develop the small nucleic acid (siRNA) drug SNK-2726, targeting angiotensinogen (AGT) for the treatment of hypertension.

siRNA-targeted therapy is an emerging therapeutic field after small molecules and antibodies, an outstanding advantage of RNA-targeted therapy is that the identification of drug candidates only needs to determine the target area related to the disease process in RNA, and for any target gene, the corresponding small nucleic acid can be designed to regulate its expression, so RNA therapy has great application potential in traditional undruggable diseases or targets, bringing revolutionary breakthr